Effect of Comorbidity Burden and Polypharmacy on Poor Functional Outcome in Acute Ischemic Stroke

[1]  OUP accepted manuscript , 2022, Age And Ageing.

[2]  P. S. Gill,et al.  Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2021, The Lancet Neurology.

[3]  C. Gerloff,et al.  Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke , 2020, European journal of neurology.

[4]  Hester F. Lingsma,et al.  Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN Registry , 2020, Neurology.

[5]  E. Warburton,et al.  Clinical frailty independently predicts early mortality after ischaemic stroke. , 2020, Age and ageing.

[6]  Michael J Lang,et al.  Revascularization and functional outcomes after mechanical thrombectomy for acute ischemic stroke in elderly patients. , 2020, Journal of neurosurgery.

[7]  C. Gerloff,et al.  Functional Outcome Following Stroke Thrombectomy in Clinical Practice. , 2019, Stroke.

[8]  J. Heo,et al.  Heterogeneity in costs and prognosis for acute ischemic stroke treatment by comorbidities , 2019, Journal of Neurology.

[9]  R. Ofori-Asenso,et al.  Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke , 2018, International journal of environmental research and public health.

[10]  E. Marsh,et al.  Chronic post-stroke fatigue: It may no longer be about the stroke itself , 2018, Clinical Neurology and Neurosurgery.

[11]  Aqeel M. Alenazi,et al.  Functional Reach, Depression Scores, and Number of Medications Are Associated With Number of Falls in People With Chronic Stroke , 2018, PM & R : the journal of injury, function, and rehabilitation.

[12]  H. Hayashi,et al.  The association of increased drugs use with activities of daily living and discharge outcome among elderly stroke patients , 2018, International Journal of Clinical Pharmacy.

[13]  Gillian E. Caughey,et al.  What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.

[14]  S. Bombois,et al.  Influence of Medication on Fatigue Six Months after Stroke , 2016, Stroke Research and Treatment.

[15]  M. Silvestrini,et al.  Charlson comorbidity index as a predictor of in-hospital death in acute ischemic stroke among very old patients: a single-cohort perspective study , 2016, Neurological Sciences.

[16]  Jeffrey J. Sutherland,et al.  Co-Prescription Trends in a Large Cohort of Subjects Predict Substantial Drug-Drug Interactions , 2015, PloS one.

[17]  U. Scoditti,et al.  Validity of the modified Charlson Comorbidity Index as predictor of short-term outcome in older stroke patients. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[18]  P. Langhorne,et al.  Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden , 2014, BMC Medicine.

[19]  H. Bøtker,et al.  Eighteen-year trends in stroke mortality and the prognostic influence of comorbidity , 2014, Neurology.

[20]  R. Payne,et al.  Prevalence of polypharmacy in a Scottish primary care population , 2014, European Journal of Clinical Pharmacology.

[21]  J. C. P. Cuenca,et al.  Charlson comorbidity index in ischemic stroke and intracerebral hemorrhage as predictor of mortality and functional outcome after 6 months. , 2013 .

[22]  Matteo Cesari,et al.  Frailty consensus: a call to action. , 2013, Journal of the American Medical Directors Association.

[23]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[24]  Sangita Kulathinal,et al.  Relative Risks for Stroke by Age, Sex, and Population Based on Follow-Up of 18 European Populations in the MORGAM Project , 2009, Stroke.

[25]  G. Schroth,et al.  Impact of comorbidity on ischemic stroke outcome , 2006, Acta neurologica Scandinavica.

[26]  T. del Ser,et al.  Evolution of Cognitive Impairment After Stroke and Risk Factors for Delayed Progression , 2005, Stroke.

[27]  David B Matchar,et al.  Charlson Index Comorbidity Adjustment for Ischemic Stroke Outcome Studies , 2004, Stroke.

[28]  K. Yau,et al.  Factors influencing survival after stroke in Western Australia , 2003, The Medical journal of Australia.

[29]  G. Hankey.  Long-Term Outcome after Ischaemic Stroke/Transient Ischaemic Attack , 2003, Cerebrovascular Diseases.

[30]  A. Mitchell,et al.  Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. , 2002, JAMA.

[31]  F. Haaijer-Ruskamp,et al.  The development of polypharmacy. A longitudinal study. , 2000, Family practice.

[32]  G. L. Paul.  Outcome studies. , 1991, Hospital & community psychiatry.

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.